PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
5.21%
Positive revenue growth while 3088.T is negative. John Neff might see a notable competitive edge here.
8.31%
Positive gross profit growth while 3088.T is negative. John Neff would see a clear operational edge over the competitor.
25.60%
Positive EBIT growth while 3088.T is negative. John Neff might see a substantial edge in operational management.
27.07%
Positive operating income growth while 3088.T is negative. John Neff might view this as a competitive edge in operations.
40.70%
Positive net income growth while 3088.T is negative. John Neff might see a big relative performance advantage.
40.71%
Positive EPS growth while 3088.T is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
40.71%
Positive diluted EPS growth while 3088.T is negative. John Neff might view this as a strong relative advantage in controlling dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
51.58%
Similar 10Y revenue/share CAGR to 3088.T's 48.95%. Walter Schloss might see both firms benefiting from the same long-term demand.
-16.43%
Negative 5Y CAGR while 3088.T stands at 24.74%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
39.52%
3Y revenue/share CAGR above 1.5x 3088.T's 12.57%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
-100.00%
Negative 10Y OCF/share CAGR while 3088.T stands at 100.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
146.54%
Similar net income/share CAGR to 3088.T's 162.55%. Walter Schloss would see parallel tailwinds or expansions for both firms.
26.35%
Below 50% of 3088.T's 105.67%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
62.87%
3Y net income/share CAGR above 1.5x 3088.T's 32.74%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
172.32%
10Y equity/share CAGR above 1.5x 3088.T's 114.26%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
21.13%
Below 50% of 3088.T's 50.92%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
67.38%
3Y equity/share CAGR above 1.5x 3088.T's 29.51%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
-25.00%
Cut dividends over 10 years while 3088.T stands at 31987.42%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
50.00%
Below 50% of 3088.T's 500.00%. Michael Burry worries the firm returns far less capital to shareholders over 5 years.
38.46%
Below 50% of 3088.T's 100.00%. Michael Burry suspects the firm invests elsewhere or can’t match the competitor’s dividend policy.
23035.00%
AR growth well above 3088.T's 1.93%. Michael Burry fears inflated revenue or higher default risk in the near future.
10.52%
We show growth while 3088.T is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
6.02%
Asset growth above 1.5x 3088.T's 2.43%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
5.55%
BV/share growth above 1.5x 3088.T's 2.66%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
1.97%
Debt growth of 1.97% while 3088.T is zero. Bruce Berkowitz sees additional leverage that must yield profitable expansions to be worthwhile.
No Data
No Data available this quarter, please select a different quarter.
-46.41%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.